Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Identifieur interne : 001664 ( Main/Exploration ); précédent : 001663; suivant : 001665Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Auteurs : Maria Luisa Montes [Espagne] ; Mark Nelson [Royaume-Uni] ; Pierre-Marie Girard [France] ; Joe Sasadeusz [Australie] ; Andrzej Horban [Pologne] ; Beatriz Grinsztejn [Brésil] ; Natalia Zakharova [Russie] ; Antonio Rivero [Espagne] ; Jacques Durant [France] ; Enrique Ortega-Gonzalez [Espagne] ; Erkki Lathouwers [Belgique] ; Katrien Janssen [Belgique] ; Sivi Ouwerkerk-Mahadevan [Belgique] ; James Witek [Oman] ; Juan González-García [Espagne]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Co-infection (traitement médicamenteux), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Femelle, Humains, Hépatite C chronique (), Hépatite C chronique (traitement médicamenteux), Infections à VIH (), Infections à VIH (traitement médicamenteux), Interféron alpha (administration et posologie), Interféron alpha (effets indésirables), Interféron alpha (pharmacocinétique), Jeune adulte, Mâle, Oligopeptides (administration et posologie), Oligopeptides (effets indésirables), Oligopeptides (pharmacocinétique), Polyéthylène glycols (administration et posologie), Polyéthylène glycols (effets indésirables), Polyéthylène glycols (pharmacocinétique), Protéines recombinantes (administration et posologie), Protéines recombinantes (effets indésirables), Protéines recombinantes (pharmacocinétique), Ribavirine (administration et posologie), Ribavirine (effets indésirables), Ribavirine (pharmacocinétique), Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- pharmacocinétique : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- traitement médicamenteux : Co-infection, Hépatite C chronique, Infections à VIH.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Hépatite C chronique, Infections à VIH, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Coinfection (drug therapy), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, HIV Infections (complications), HIV Infections (drug therapy), Hepatitis C, Chronic (complications), Hepatitis C, Chronic (drug therapy), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (pharmacokinetics), Male, Middle Aged, Oligopeptides (administration & dosage), Oligopeptides (adverse effects), Oligopeptides (pharmacokinetics), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Polyethylene Glycols (pharmacokinetics), Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Recombinant Proteins (pharmacokinetics), Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (pharmacokinetics), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , pharmacokinetics : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- complications : HIV Infections, Hepatitis C, Chronic.
- drug therapy : Coinfection, HIV Infections, Hepatitis C, Chronic.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.
DOI: 10.1093/jac/dkv323
PubMed: 26483516
Affiliations:
- Australie, Belgique, Brésil, Espagne, France, Oman, Pologne, Royaume-Uni, Russie
- Angleterre, Communauté de Madrid, Grand Londres, Provence-Alpes-Côte d'Azur, État de Rio de Janeiro, Île-de-France
- Londres, Madrid, Nice, Paris, Rio de Janeiro
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002538
- to stream PubMed, to step Curation: 002470
- to stream PubMed, to step Checkpoint: 002470
- to stream Ncbi, to step Merge: 002C42
- to stream Ncbi, to step Curation: 002C42
- to stream Ncbi, to step Checkpoint: 002C42
- to stream Main, to step Merge: 001659
- to stream Main, to step Curation: 001664
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.</title><author><name sortKey="Montes, Maria Luisa" sort="Montes, Maria Luisa" uniqKey="Montes M" first="Maria Luisa" last="Montes">Maria Luisa Montes</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name><affiliation wicri:level="3"><nlm:affiliation>Chelsea and Westminster Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chelsea and Westminster Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Girard, Pierre Marie" sort="Girard, Pierre Marie" uniqKey="Girard P" first="Pierre-Marie" last="Girard">Pierre-Marie Girard</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Sasadeusz, Joe" sort="Sasadeusz, Joe" uniqKey="Sasadeusz J" first="Joe" last="Sasadeusz">Joe Sasadeusz</name><affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name><affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name><affiliation wicri:level="3"><nlm:affiliation>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro</wicri:regionArea><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation></author><author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name><affiliation wicri:level="1"><nlm:affiliation>Saint-Petersburg AIDS Center, St Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Saint-Petersburg AIDS Center, St Petersburg</wicri:regionArea><wicri:noRegion>St Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba</wicri:regionArea><wicri:noRegion>Córdoba</wicri:noRegion></affiliation></author><author><name sortKey="Durant, Jacques" sort="Durant, Jacques" uniqKey="Durant J" first="Jacques" last="Durant">Jacques Durant</name><affiliation wicri:level="3"><nlm:affiliation>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Ortega Gonzalez, Enrique" sort="Ortega Gonzalez, Enrique" uniqKey="Ortega Gonzalez E" first="Enrique" last="Ortega-Gonzalez">Enrique Ortega-Gonzalez</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Lathouwers, Erkki" sort="Lathouwers, Erkki" uniqKey="Lathouwers E" first="Erkki" last="Lathouwers">Erkki Lathouwers</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Janssen, Katrien" sort="Janssen, Katrien" uniqKey="Janssen K" first="Katrien" last="Janssen">Katrien Janssen</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development LLC, Titusville, NJ, USA jwitek@its.jnj.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Janssen Research & Development LLC, Titusville, NJ</wicri:regionArea><wicri:noRegion>NJ</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez Garcia, Juan" sort="Gonzalez Garcia, Juan" uniqKey="Gonzalez Garcia J" first="Juan" last="González-García">Juan González-García</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26483516</idno><idno type="pmid">26483516</idno><idno type="doi">10.1093/jac/dkv323</idno><idno type="wicri:Area/PubMed/Corpus">002538</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002538</idno><idno type="wicri:Area/PubMed/Curation">002470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002470</idno><idno type="wicri:Area/PubMed/Checkpoint">002470</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002470</idno><idno type="wicri:Area/Ncbi/Merge">002C42</idno><idno type="wicri:Area/Ncbi/Curation">002C42</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C42</idno><idno type="wicri:Area/Main/Merge">001659</idno><idno type="wicri:Area/Main/Curation">001664</idno><idno type="wicri:Area/Main/Exploration">001664</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.</title><author><name sortKey="Montes, Maria Luisa" sort="Montes, Maria Luisa" uniqKey="Montes M" first="Maria Luisa" last="Montes">Maria Luisa Montes</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name><affiliation wicri:level="3"><nlm:affiliation>Chelsea and Westminster Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chelsea and Westminster Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Girard, Pierre Marie" sort="Girard, Pierre Marie" uniqKey="Girard P" first="Pierre-Marie" last="Girard">Pierre-Marie Girard</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital St Antoine and INSERM, UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Sasadeusz, Joe" sort="Sasadeusz, Joe" uniqKey="Sasadeusz J" first="Joe" last="Sasadeusz">Joe Sasadeusz</name><affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name><affiliation wicri:level="1"><nlm:affiliation>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Warsaw Medical University and Hospital of Infectious Diseases, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name><affiliation wicri:level="3"><nlm:affiliation>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro</wicri:regionArea><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation></author><author><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name><affiliation wicri:level="1"><nlm:affiliation>Saint-Petersburg AIDS Center, St Petersburg, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Saint-Petersburg AIDS Center, St Petersburg</wicri:regionArea><wicri:noRegion>St Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía/IMIBIC, Córdoba</wicri:regionArea><wicri:noRegion>Córdoba</wicri:noRegion></affiliation></author><author><name sortKey="Durant, Jacques" sort="Durant, Jacques" uniqKey="Durant J" first="Jacques" last="Durant">Jacques Durant</name><affiliation wicri:level="3"><nlm:affiliation>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Infectious Diseases Department, L'Archet Hospital, University of Nice, Nice</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Ortega Gonzalez, Enrique" sort="Ortega Gonzalez, Enrique" uniqKey="Ortega Gonzalez E" first="Enrique" last="Ortega-Gonzalez">Enrique Ortega-Gonzalez</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital General Universitario, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Lathouwers, Erkki" sort="Lathouwers, Erkki" uniqKey="Lathouwers E" first="Erkki" last="Lathouwers">Erkki Lathouwers</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Janssen, Katrien" sort="Janssen, Katrien" uniqKey="Janssen K" first="Katrien" last="Janssen">Katrien Janssen</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development LLC, Titusville, NJ, USA jwitek@its.jnj.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Janssen Research & Development LLC, Titusville, NJ</wicri:regionArea><wicri:noRegion>NJ</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez Garcia, Juan" sort="Gonzalez Garcia, Juan" uniqKey="Gonzalez Garcia J" first="Juan" last="González-García">Juan González-García</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Medicina Interna, Unidad de VIH, IdiPAZ, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (pharmacokinetics)</term><term>Coinfection (drug therapy)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Female</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>Hepatitis C, Chronic (complications)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (pharmacokinetics)</term><term>Male</term><term>Middle Aged</term><term>Oligopeptides (administration & dosage)</term><term>Oligopeptides (adverse effects)</term><term>Oligopeptides (pharmacokinetics)</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Polyethylene Glycols (pharmacokinetics)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (pharmacokinetics)</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (pharmacokinetics)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (pharmacocinétique)</term><term>Co-infection (traitement médicamenteux)</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Femelle</term><term>Humains</term><term>Hépatite C chronique ()</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (effets indésirables)</term><term>Interféron alpha (pharmacocinétique)</term><term>Jeune adulte</term><term>Mâle</term><term>Oligopeptides (administration et posologie)</term><term>Oligopeptides (effets indésirables)</term><term>Oligopeptides (pharmacocinétique)</term><term>Polyéthylène glycols (administration et posologie)</term><term>Polyéthylène glycols (effets indésirables)</term><term>Polyéthylène glycols (pharmacocinétique)</term><term>Protéines recombinantes (administration et posologie)</term><term>Protéines recombinantes (effets indésirables)</term><term>Protéines recombinantes (pharmacocinétique)</term><term>Ribavirine (administration et posologie)</term><term>Ribavirine (effets indésirables)</term><term>Ribavirine (pharmacocinétique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term><term>Hépatite C chronique</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Hépatite C chronique</term><term>Infections à VIH</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Brésil</li><li>Espagne</li><li>France</li><li>Oman</li><li>Pologne</li><li>Royaume-Uni</li><li>Russie</li></country><region><li>Angleterre</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Provence-Alpes-Côte d'Azur</li><li>État de Rio de Janeiro</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Madrid</li><li>Nice</li><li>Paris</li><li>Rio de Janeiro</li></settlement></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Montes, Maria Luisa" sort="Montes, Maria Luisa" uniqKey="Montes M" first="Maria Luisa" last="Montes">Maria Luisa Montes</name></region><name sortKey="Gonzalez Garcia, Juan" sort="Gonzalez Garcia, Juan" uniqKey="Gonzalez Garcia J" first="Juan" last="González-García">Juan González-García</name><name sortKey="Ortega Gonzalez, Enrique" sort="Ortega Gonzalez, Enrique" uniqKey="Ortega Gonzalez E" first="Enrique" last="Ortega-Gonzalez">Enrique Ortega-Gonzalez</name><name sortKey="Rivero, Antonio" sort="Rivero, Antonio" uniqKey="Rivero A" first="Antonio" last="Rivero">Antonio Rivero</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Girard, Pierre Marie" sort="Girard, Pierre Marie" uniqKey="Girard P" first="Pierre-Marie" last="Girard">Pierre-Marie Girard</name></region><name sortKey="Durant, Jacques" sort="Durant, Jacques" uniqKey="Durant J" first="Jacques" last="Durant">Jacques Durant</name></country><country name="Australie"><noRegion><name sortKey="Sasadeusz, Joe" sort="Sasadeusz, Joe" uniqKey="Sasadeusz J" first="Joe" last="Sasadeusz">Joe Sasadeusz</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Horban, Andrzej" sort="Horban, Andrzej" uniqKey="Horban A" first="Andrzej" last="Horban">Andrzej Horban</name></noRegion></country><country name="Brésil"><region name="État de Rio de Janeiro"><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name></region></country><country name="Russie"><noRegion><name sortKey="Zakharova, Natalia" sort="Zakharova, Natalia" uniqKey="Zakharova N" first="Natalia" last="Zakharova">Natalia Zakharova</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Lathouwers, Erkki" sort="Lathouwers, Erkki" uniqKey="Lathouwers E" first="Erkki" last="Lathouwers">Erkki Lathouwers</name></noRegion><name sortKey="Janssen, Katrien" sort="Janssen, Katrien" uniqKey="Janssen K" first="Katrien" last="Janssen">Katrien Janssen</name><name sortKey="Ouwerkerk Mahadevan, Sivi" sort="Ouwerkerk Mahadevan, Sivi" uniqKey="Ouwerkerk Mahadevan S" first="Sivi" last="Ouwerkerk-Mahadevan">Sivi Ouwerkerk-Mahadevan</name></country><country name="Oman"><noRegion><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001664 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001664 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26483516
|texte= Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26483516" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |